washington reuters us president donald trump ’s choice lead important health agency say thursday way pharmaceutical company classify product generic brand need review order help hold government spending -PRON- cite mylan nv ’s epipen emergency allergy treatment
seema verma trump ’s nominee lead center medicare medicaid services cms answer question whether us government negotiate pharmaceutical company drug price
" think happen epipen issue disturbing " verma say -PRON- confirmation hearing senate finance committee
" idea perhaps medicaid program struggle pay program -PRON- could potentially receive rebate disturbing -PRON- " mylan criticize list epipen medicaid generic product even though -PRON- list -PRON- food drug administration branded product
classification lead mylan ’s pay significantly small rebate medicaid healthcare program poor epipen classify brand
" would like review process place term classification term brand generic ensure type thing happen " verma say
cms say last year -PRON- " expressly advise " mylan drugmaker improperly classify epipen
mylan say last month us antitrust authority launch investigation epipen
company say suggestion -PRON- take inappropriate unlawful action prevent generic competition " without merit " mylan also come fire raise price twopack epipen 600 last summer 100 2008
mylan begin sell generic version epipen 300 per twopack december
verma also say -PRON- would produce record communication agency mylan question republican senator chuck grassley
statement grassley ’s office say mylan overcharge state taxpayer " potentially hundred million dollar " democrats pleased verma ’s sidestep question senator debbie stabenow whether -PRON- agree trump government negotiate drug company price drug cover medicare healthcare program elderly disabled
" think ’ simple yes answer " verma say
" goal make sure -PRON- get affordable price -PRON- senior "